FTSE 100 succumbs to global profit-taking, closes firmly in red
The UK blue chip index closed down 108.45 points at 7.334, which had been the session low
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 17 of 21
Archive
Proactive news snapshot: Stratex International, Diversified Gas & Oil, Keywords Studios …
A glance at some of the day's highlights from the Proactive Investors newswire
Spectra Systems counting the coins as it says 2017 will be ahead of expectations
Some of the main news-driven risers and fallers on Thursday...
Faron extends patent protection for Clevegen cancer immunotherapy
"The grant of this patent serves to protect the innovative mechanism underlying Clevegen, which will be important in realising the potential our second wholly-owned product promises"
Investments and investor services
FTSE 100 closes in red but broadcaster ITV shines
Footsie finished down over 43 points at 7,490, while FTSE 250 was also lower - down around 58 points at 20,185.
Archive
Proactive news snapshot: Porta Communications, Telit Communications, Concepta ...
A glance at some of the day's highlights from the Proactive Investors newswire
Sopheon tops London risers as it raises 2017 guidance
Some of the main news-driven risers and fallers in London on Monday...
Faron Pharmaceuticals drug receives fast-track designation from US regulator
This accelerated review is designed to get drugs to areas of unmet medical need
FTSE 100 closes higher, just, with miners in support
The FTSE 100, dragged higher by the miners, got off to a strong start today, but closed juts about six points higher
Archive
Proactive news snapshot: Empresaria Group, Directa Plus, ImmuPharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharmaceuticals looks to Clevegen opportunity after Traumakine disappointment
Clevegen has shown no toxicologically relevant changes in any subject in dose escalation studies.
Empresaria surges after a reassuring trading statement
Premaitha is given a fillip by permission to appeal against High Court's decision on patent dispute
Faron Pharmaceuticals makes more headway with the US regulator
Chief executive Dr Markku Jalkanen said he was pleased with the latest approval from the Food & Drug Administration
Investments and investor services
FTSE 100 closes in the red as sterling booms
“If he intended it, Treasury Secretary Steven Mnuchin has done a first class job of whacking the dollar,” declared Neil Wilson at ETX Capital. .
Archive
Proactive news snapshot: Horse Hill, Kromek Group, Base Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Fusion Antibodies up another 30% after posting a 35% leap on Monday's AIM debut
A look at some of the biggest risers and fallers in London on Tuesday
Faron Pharmaceuticals receives clinical trial green light in second indication for lead drug
Traumakine is being tested for safety and efficacy in patients with multi-organ failure - this is a potential second indication for the drug
FTSE 100 closes in positive territory but off session highs
The UK blue chip index closed around seven points higher at 7,544, below the day’s peak of 7,563
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Scancell Holdings soars after "stunning endorsement" of its ImmunoBody platform
Cancer Research UK was immensely impressed with the company and its technology